ArticleMolecular cancer therapeutics2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL.International journal of molecular sciences · 2026Article
- Integrated Bioinformatics and Experimental Validation of Post-Translational Modification-Related Biomarkers in Myocardial Ischemia-Reperfusion Injury.Journal of cardiovascular translational research · 2026Article
- Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.Leukemia · 2026Article
- Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma.Acta neuropathologica communications · 2026Article
- A coordinated multi-target approach based on chondroitin sulphate nano-selenium mitigates Alzheimer's disease pathologies in APP/PS1 mice.Frontiers in pharmacology · 2026Article
- Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).Cancer biology & therapy · 2025Article
- Modulation of the PI3K/Akt signaling pathway by resveratrol in cancer: molecular mechanisms and therapeutic opportunity.Discover oncology · 2025Review
- Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6.Cell communication and signaling : CCS · 2025Article
- Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.Non-coding RNA research · 2025Review
- Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITDCell communication and signaling : CCS · 2024Article
- Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.Cancer research communications · 2024Article
- PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.The Journal of clinical investigation · 2023Article
- Protein Phosphatase 2a Inhibits Gastric Cancer Cell Glycolysis by Reducing MYC Signaling.Cell biochemistry and biophysics · 2023Article
- High Throughput FISH Screening Identifies Small Molecules That Modulate Oncogenic lncRNA MALAT1 via GSK3B and hnRNPs.Non-coding RNA · 2023Article
- From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer.Frontiers in genetics · 2023Review
- Revving the engine: PKB/AKT as a key regulator of cellular glucose metabolism.Frontiers in physiology · 2023Review
- Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma.Frontiers in oncology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution.
Mario ScarpaThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Prerna SinghThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Christopher M BaileyDepartment of Surgery and.
Jonelle K LeeThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Shivani KapoorThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Rena G LapidusThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Sandrine NiyongereThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Jaya SangodkarDivision of Genetic Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
Yin WangThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Danilo PerrottiThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Goutham NarlaDivision of Genetic Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
Maria R BaerThe University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, mbaer@umm.edu.
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Funding
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0MEXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9MStructural and molecular determinants of protein phosphatase 2A in Alzheimer's DiseaseR01CA240993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM, TAYLOR, DEREK JAMES · 2019 to 2023
$3.4MRole of Protein Phosphatase 2A in Aortic AneurysmR01HL144741 · NHLBI · EMORY UNIVERSITY · PI LIN, ZHIYONG, NARLA, GOUTHAM · 2019 to 2022
$2.2MSmall Molecule Activators of PP2A (SMAPs) for Prostate Cancer TherapyR01CA181654 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NARLA, GOUTHAM · 2015 to 2019
$1.9MRole of microRNAs in the regulation of CML stem cell survival and self renewalR01CA163800 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI PERROTTI, DANILO · 2012 to 2017
$1.6MInhibition of Pim kinases in acute myeloid leukemiaI01BX002184 · VA · BALTIMORE VA MEDICAL CENTER · PI BAER, MARIA R · 2015 to 2018
–BLRD VA I01 BX002184NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA163800NCI NIH HHS R01 CA181654NCI NIH HHS R01 CA240993NHLBI NIH HHS R01 HL144741NIGMS NIH HHS R25 GM055036
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCell ProliferationGenes, mycGlycogen Synthase Kinase 3 betaHumansMiceMice, Inbred NODProtein Kinase InhibitorsProtein Phosphatase 2Proto-Oncogene Proteins c-aktProto-Oncogene Proteins c-pim-1Signal TransductionTransfectionGlycogen Synthase Kinase 3 betaProtein Kinase InhibitorsProtein Phosphatase 2Proto-Oncogene Proteins c-aktProto-Oncogene Proteins c-pim-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.